Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.31
-0.50 (-2.66%)
At close: Dec 5, 2025, 4:00 PM EST
18.31
0.00 (0.00%)
After-hours: Dec 5, 2025, 7:36 PM EST
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 33.63, with a low estimate of 12 and a high estimate of 44. The average target predicts an increase of 83.67% from the current stock price of 18.31.
Analyst Consensus: Buy
* Price targets were last updated on Oct 22, 2025.
Analyst Ratings
The average analyst rating for Summit Therapeutics stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 10 | 9 | 9 | 9 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 2 | 2 |
| Sell | 1 | 1 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 16 | 18 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +118.46% | Oct 22, 2025 |
| Barclays | Barclays | Sell Maintains $13 → $16 | Sell | Maintains | $13 → $16 | -12.62% | Oct 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +118.46% | Oct 21, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $35 → $40 | Strong Buy | Maintains | $35 → $40 | +118.46% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
18.90M
EPS This Year
-1.23
from -0.31
EPS Next Year
-0.99
from -1.23
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 86.1M | ||||
| Avg | n/a | 18.9M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.14 | -0.59 | ||||
| Avg | -1.23 | -0.99 | ||||
| Low | -1.45 | -1.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.